-
Information-Publications
-
A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modelingDetails -
A Novel Double-Stranded DNA Deaminase-Based and Transcriptional Activator-Assisted Nuclear and Mitochondrial Cytosine Base Editors with Expanded TargetDetails -
Enhancement of prime editing via xrRNA motif-joined pegRNADetails -
High PKD2 predicts poor prognosis in lung adenocarcinoma via promoting Epithelial–mesenchymal TransitionDetails -
Gelation of cytoplasmic expanded CAG RNA repeats suppresses global protein synthesisDetails -
Characterisation of forkhead box protein A3 as a key transcription factor for hepatocyte regenerationDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands
Back
